Ninh Van Bay Travel Real Estate JSC (HOSE:NVT)
Vietnam · Delayed Price · Currency is VND 8,220.00
+120.00 (1.48%)
At close: Aug 4, 2025
CTI BioPharma Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2015 | FY 2014 | FY 2013 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | 2016 - 2020 |
| 433,406 | 410,702 | 377,060 | 96,077 | 210,546 | 207,294 | Upgrade | |
Revenue Growth (YoY) | 351.10% | 8.92% | 292.46% | -54.37% | 1.57% | 0.65% | Upgrade |
Cost of Revenue | 190,488 | 187,092 | 184,431 | 70,087 | 112,991 | 111,658 | Upgrade |
Gross Profit | 242,919 | 223,611 | 192,630 | 25,990 | 97,555 | 95,636 | Upgrade |
Selling, General & Admin | 147,249 | 142,550 | 130,686 | 123,986 | 99,275 | 87,717 | Upgrade |
Operating Expenses | 147,249 | 142,550 | 130,686 | 123,986 | 99,275 | 87,717 | Upgrade |
Operating Income | 95,669 | 81,061 | 61,943 | -97,995 | -1,720 | 7,920 | Upgrade |
Interest Expense | -22,142 | -23,675 | -31,959 | -37,731 | -1,477 | -1,270 | Upgrade |
Interest & Investment Income | 8,308 | 4,731 | 6,081 | 20,527 | 29,028 | 33,502 | Upgrade |
Earnings From Equity Investments | - | - | - | -2,561 | -3,361 | -767.54 | Upgrade |
Currency Exchange Gain (Loss) | -672.6 | -672.6 | -2,288 | -155 | -212.76 | -144.76 | Upgrade |
Other Non Operating Income (Expenses) | -2,026 | -17,776 | 634.56 | -142.58 | 3,380 | 828.89 | Upgrade |
EBT Excluding Unusual Items | 79,136 | 43,670 | 34,412 | -118,057 | 25,638 | 40,068 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 18,360 | -4,923 | - | -264.46 | Upgrade |
Gain (Loss) on Sale of Assets | 72.03 | 72.03 | -511.4 | - | - | - | Upgrade |
Pretax Income | 79,208 | 43,742 | 52,260 | -122,980 | 25,638 | 39,804 | Upgrade |
Income Tax Expense | 24,174 | 20,829 | 16,427 | 3,445 | 3,340 | -789.64 | Upgrade |
Earnings From Continuing Operations | 55,035 | 22,912 | 35,833 | -126,425 | 22,298 | 40,593 | Upgrade |
Minority Interest in Earnings | -45,808 | -32,652 | -30,225 | -1,230 | -16,686 | -19,979 | Upgrade |
Net Income | 9,227 | -9,740 | 5,608 | -127,655 | 5,612 | 20,614 | Upgrade |
Net Income to Common | 9,227 | -9,740 | 5,608 | -127,655 | 5,612 | 20,614 | Upgrade |
Net Income Growth | - | - | - | - | -72.78% | - | Upgrade |
Shares Outstanding (Basic) | 91 | 91 | 91 | 91 | 91 | 83 | Upgrade |
Shares Outstanding (Diluted) | 91 | 91 | 91 | 91 | 92 | 83 | Upgrade |
Shares Change (YoY) | - | - | - | -1.45% | 10.51% | 37.36% | Upgrade |
EPS (Basic) | 101.96 | -107.62 | 61.97 | -1410.55 | 62.01 | 248.05 | Upgrade |
EPS (Diluted) | 101.57 | -108.00 | 61.97 | -1410.55 | 61.00 | 248.00 | Upgrade |
EPS Growth | - | - | - | - | -75.40% | - | Upgrade |
Free Cash Flow | 121,363 | 111,056 | 96,390 | -8,578 | -58,949 | 4,670 | Upgrade |
Free Cash Flow Per Share | 1341.02 | 1227.14 | 1065.09 | -94.78 | -641.91 | 56.20 | Upgrade |
Gross Margin | 56.05% | 54.45% | 51.09% | 27.05% | 46.33% | 46.14% | Upgrade |
Operating Margin | 22.07% | 19.74% | 16.43% | -102.00% | -0.82% | 3.82% | Upgrade |
Profit Margin | 2.13% | -2.37% | 1.49% | -132.87% | 2.67% | 9.94% | Upgrade |
Free Cash Flow Margin | 28.00% | 27.04% | 25.56% | -8.93% | -28.00% | 2.25% | Upgrade |
EBITDA | 149,647 | 133,593 | 109,608 | -20,079 | 38,926 | 46,961 | Upgrade |
EBITDA Margin | 34.53% | 32.53% | 29.07% | -20.90% | 18.49% | 22.65% | Upgrade |
D&A For EBITDA | 53,977 | 52,532 | 47,664 | 77,916 | 40,646 | 39,041 | Upgrade |
EBIT | 95,669 | 81,061 | 61,943 | -97,995 | -1,720 | 7,920 | Upgrade |
EBIT Margin | 22.07% | 19.74% | 16.43% | -102.00% | -0.82% | 3.82% | Upgrade |
Effective Tax Rate | 30.52% | 47.62% | 31.43% | - | 13.03% | - | Upgrade |
Revenue as Reported | 433,406 | 410,702 | 377,060 | 96,077 | 210,546 | 207,294 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.